What is APVO's dilution risk score?

APVO has a latest available DilutionScore record of 41/100, categorized as medium dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for APVO, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for APVO?

DilutionWatch tracks 25 SEC filing types for APVO including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect APVO shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For APVO, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for APVO tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for APVO. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

APVO Dilution Risk Score: 41/100 (MEDIUM)

Score Breakdown

📋 Offering Ability

💰 Cash Runway

📊 Float Risk

⚠️ Warrant Exposure

🔄 Convertible Debt

Dilution Forecast

Forecast data not available for this ticker.

Market Data

Market CapN/A

Shares Outstanding1.56M

Float935.4K

CashN/A

DebtN/A

Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

Field	Current Value	Basis
DilutionScore	41/100	DilutionWatch score record
Shares Outstanding	1.56M	Verified float table or market cache
Public Float	935.4K	Verified float table or market cache
Market Cap	Not available	Market data cache
Cash Runway	Not available	DilutionWatch score inputs
Shelf Capacity	None in current score inputs	SEC-derived dilution fields
ATM Capacity	None in current score inputs	SEC-derived dilution fields
Outstanding Warrants	None in current score inputs	SEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 1.

Recent SEC source mix: XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

12 institutional holders · 497.2K shares

#1 Point72 Asset Management, L.P. 299.9K shares

#2 DRW Securities, LLC 131.5K shares

#3 Virtu Financial LLC 38.3K shares

+ 9 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

No current FINRA short-interest record is available for this ticker.

Recent SEC Activity

xbrl XBRL WARRANT 2026-06-30

Full SEC filing analysis available with free account →

Recent News

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development ACCESS Newswire · Sep 24, 2026

Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML InvestorsHub · Sep 03, 2026

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP5 ACCESS Newswire · Sep 03, 2026

APVO: Focusing on Three Key Areas of Development Zacks Small Cap Research · Aug 24, 2026

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results ACCESS Newswire · Aug 14, 2026

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Mill ACCESS Newswire · Aug 13, 2026

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gros ACCESS Newswire · Aug 12, 2026

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targe ACCESS Newswire · Jul 27, 2026

Factual APVO Dilution Snapshot

Aptevo Therapeutics Inc. (APVO) has a DilutionScore of 41/100, rated Medium dilution risk. Score date: October 04, 2026.

Recent SEC activity tracked for APVO: xbrl on 2026-06-30.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

APVO's DilutionScore has held steady at 41/100 (Medium risk) for 90 consecutive days across the tracked period.

Period	Score	Risk Level	Duration
Jul 07 – Oct 04, 2026	41/100	MEDIUM	90 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Track APVO Dilution Risk in Real-Time

DilutionWatch monitors SEC filings 24/7 and alerts you the moment APVO files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.

Start Tracking APVO — Free

Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously